IPSEN Aktie

 

Find insight on Ipsen, UltraGreen.ai, Neuren Pharmaceuticals in the latest Market Talks covering Health Care....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

PARIS (dpa-AFX) - Ipsen (IPSEF.PK) said Monday it has agreed to acquire Kartos Therapeutics for up to $1.75 billion, expanding its hematology pipeline with navtemadlin, an investigational treatmen......

The deal adds navtemadlin—a drug candidate for a rare blood cancer in late-stage clinical trials—to Ipsen's oncology pipeline....

The deal adds navtemadlin—a drug candidate for a rare blood cancer in late-stage clinical trials—to Ipsen's oncology pipeline....

PARIS, FRANCE AND REDWOOD CITY, U.S., 29 JUNE 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) and Kartos Therapeutics, announced today they have entered into a definitive merger agreement under which Ipsen has agreed to acquire Kartos Therapeutics. The acquisition adds navtemadlin, an investigational MDM2 inhibitor designed to restore the natural tumor-suppressing function of p53, a critical tumor-suppressor in myelofibrosis. Data show strong therapeutic potential of navtemadlin for intermediate and high-risk TP53 wild-type (wt) myelofibrosis as an add-on treatment for patients with a suboptimal response to standard of care ruxolitinib....

Nach dem Tod von Henri Beaufour geht dessen milliardenschwerer Pharma-Anteil von Ipsen an eine Luxemburger Stiftung und einen Offshore-Trust. Die Konstruktion wirft Fragen auf....

One of the billionaire heirs behind French drugmaker Ipsen SA has left his $4 billion fortune to a Luxembourg charity and an offshore trust, clouding the outlook for the company's long-term control and ownership....

Aggregated presentation by day and by market...

Aggregated presentation by day and by market...

Monthly information relative to the total number of voting rights and shares composing the share capital...

Aggregated presentation by day and by market...

The cervical dystonia market is expected to increase due to an increase in disease prevalence during the forecast period. Additionally, the expected launch of emerging therapies such as ABP-450 (prabotulinumtoxinA) (AEON Biopharma), IPN10200 (Ipsen), MTR-601 (Mitra Biosciences), VIM0423......

Aggregated presentation by day and by market...

Ipsen announces the launch of an employee shareholding plan...

PARIS, FRANCE, 28 MAY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) today announced the presentation of new late-breaking results from the ELATIVE® Phase III trial and two real-world studies at the European Association for the Study of the Liver (EASL) congress. Together, these data further strengthen the growing body of evidence establishing IQIRVO® as the only second-line primary biliary cholangitis (PBC) treatment providing rapid and robust alkaline phosphatase (ALP) reduction with fatigue improvement (in patients with moderate-to-severe fatigue at baseline) and pruritus relief....

Aggregated presentation by day and by market...

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 25, 2026 – GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today highlights its broad participation at EASL Congress 2026. This visibility reflects both its scientific momentum and its active involvement in the ACLF ecosystem, as well as its position at an inflection point in MASH, while also highlighting the continuous progress made in PBC, driven by its partner Ipsen....